130 related articles for article (PubMed ID: 29932031)
1. Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors.
Kim C; Kim E
Curr Med Chem; 2019; 26(42):7623-7640. PubMed ID: 29932031
[TBL] [Abstract][Full Text] [Related]
2. Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design.
Machiraju PK; Yedla P; Gubbala SP; Bohari T; Abdul JKV; Xu S; Patel R; Chittireddy VRR; Boppana K; Jagarlapudi SARP; Neamati N; Syed R; Amanchy R
Comput Biol Chem; 2019 Jun; 80():374-383. PubMed ID: 31103918
[TBL] [Abstract][Full Text] [Related]
3. Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.
Ravichandran S; Luke BT; Collins JR
J Mol Graph Model; 2015 Apr; 57():36-48. PubMed ID: 25635590
[TBL] [Abstract][Full Text] [Related]
4. An integrated molecular modeling approach for in silico design of new tetracyclic derivatives as ALK inhibitors.
Peddi SR; Sivan SK; Manga V
J Recept Signal Transduct Res; 2016 Oct; 36(5):488-504. PubMed ID: 26758803
[TBL] [Abstract][Full Text] [Related]
5. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
[TBL] [Abstract][Full Text] [Related]
6. Selective mechanisms and molecular design of 2,4 Diarylaminopyrimidines as ALK inhibitors.
Tu J; Song LT; Zhai HL; Wang J; Zhang XY
Int J Biol Macromol; 2018 Oct; 118(Pt A):1149-1156. PubMed ID: 30001602
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors.
Raeppel SL; Therrien E; Raeppel F
Bioorg Med Chem Lett; 2015 Sep; 25(17):3706-10. PubMed ID: 26112445
[TBL] [Abstract][Full Text] [Related]
8. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
9. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
[TBL] [Abstract][Full Text] [Related]
10. Identification of type II and III DDR2 inhibitors.
Richters A; Nguyen HD; Phan T; Simard JR; Grütter C; Engel J; Rauh D
J Med Chem; 2014 May; 57(10):4252-62. PubMed ID: 24754677
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
12. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification.
Ke YY; Singh VK; Coumar MS; Hsu YC; Wang WC; Song JS; Chen CH; Lin WH; Wu SH; Hsu JT; Shih C; Hsieh HP
Sci Rep; 2015 Jun; 5():11702. PubMed ID: 26118648
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor.
Raeppel SL; Raeppel F; Therrien E
Bioorg Med Chem Lett; 2015 Jun; 25(12):2527-31. PubMed ID: 25953155
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
Ibrahim MAA; Abdelrahman AHM; Hassan AMA
Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
[TBL] [Abstract][Full Text] [Related]
15. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures.
Li J; Halfter K; Zhang M; Saad C; Xu K; Bauer B; Huang Y; Shi L; Mansmann UR
BMC Cancer; 2019 Jun; 19(1):600. PubMed ID: 31208363
[TBL] [Abstract][Full Text] [Related]
16. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors.
Zhou S; Li Y; Hou T
J Chem Inf Model; 2013 Apr; 53(4):982-96. PubMed ID: 23506306
[TBL] [Abstract][Full Text] [Related]
18. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and structure-activity relationship of diaryl-ureas with novel isoxazol[3,4-b]pyridine-3-amino-structure as multi-target inhibitors against receptor tyrosine kinase.
Shi ZH; Liu FT; Tian HZ; Zhang YM; Li NG; Lu T
Bioorg Med Chem; 2018 Sep; 26(16):4735-4744. PubMed ID: 30121211
[TBL] [Abstract][Full Text] [Related]
20. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
Chaudhari P; Bari S
Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
